RecruitingPhase 3NCT03647072

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.

Sponsor

Sherief Abd-Elsalam

Enrollment

60 participants

Start Date

Aug 1, 2018

Study Type

INTERVENTIONAL

Conditions

Lymphoma

Summary

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is comparing two types of stomach-protective medications — proton pump inhibitors (PPIs, like omeprazole) versus histamine blockers (like ranitidine) — given alongside chemotherapy for a type of blood cancer called DLBCL lymphoma, to see which protects the stomach better and affects treatment outcomes. **You may be eligible if...** - You have been diagnosed with DLBCL (Diffuse Large B-Cell Lymphoma) - You have no other major health problems (no significant comorbidities) **You may NOT be eligible if...** - You are pregnant - You have a peptic ulcer (stomach ulcer) - You have severe heart disease - You have osteoporosis (weak or brittle bones) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.